Antiphospholipid-antibodies and other thrombophilic defects in patients with a history of early onset severe preeclampsia or HELLP-syndrome;Antiphospholipid-antikorper und andere hamostaseologische veranderungen bei patientinnen mit fruher schwerer praeklampsie oder HELLP-syndrom in der anamnese

Geburtshilfe und Frauenheilkunde

Volumn 60, Issue 2, 2000, Pages 95-100

  Heilmann, L ^a   Schneider, D M ^a   Tempelhoff, C F ^b   Kuse, S ^a  

^a Ceburtsh Stadtkrankenhaus Rüsselsheim ^*

^b Gesundheits und Pflegezentrum Russelsheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HELLP SYNDROME; HUMAN; MAJOR CLINICAL STUDY; PREECLAMPSIA; SPONTANEOUS ABORTION; THROMBOPHILIA;

EID: 0033999649     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-5987     Document Type: Article

References (35)

1. Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, van Assche A, Vermylen J. High dose intravenous immunglobulin treatment of a pregnant patient with an antiphospholipid syndrome: Immunological changes associated with a successful outcome. Thromb Haemostas 1994; 71: 741 -747
2. Backos M, Chilocott I, Rai R. Reagan L Pregnancy complication in women with recurrent miscarriage and antiphospholipid antibodies treated with aspirin and heparin. Hum Reprod 1997; 12: 61
3. Bernstein IM, Ziegler W, Stirewalt WS, BrunnstedJ, Ward K. Angitensinogen genotype and plasma volume in multigravid women. Obstet Cynecol 1998; 92:171-173
4. Bernstein IM, Meyer MC, Osol G, Ward K. Intolerance to volume expansion: A theorized mechanism for the development of preeclampsia. Obstet Gynecol 1998; 92: 306-308
5. Bertina RA, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
6. Birdsall M, Pattison N, Chamley L Antiphospholipid antibodies in pregnancy. AustrNZJ Obstet Gynecol 1992; 32: 328-330
7. Bokarewa MI, Blombäck M, Bremme K. Phospholipid antibodies and resistance to activated protein C in women with thrombophilia. Blood Coag Fibrinol 1995; 6:417-422
8. Branch DW, Druzin M, SpinnatoJM, HargerJ, Mais P, Peaceman A. Randomized, placebo controlled trial of intravenous immunoglobulin (IVIG) in antiphospholipid syndrome (APS) in pregnancy. A progress report. Lupus 1996; 5: 553
9. Branch DW, Silver RM, Backwell JL, Reading JC, Scot JR. Outcome of treated pregnancies in women with antiphosphoupid syndrome. An update of the Utah experience. Obstet Gynecol 1992; 80: 614-620
10. Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev 1997:11:72-79
11. Clark AL, Branch DW. Silver RM, Harris EN, Pierangelli S, Spinnato JA. Pregnancy complicated by the antiphospholipid syndrome: Outcome intravenous immunoglobuline therapy. Obstet Gynecol 1999;93:437-441
12. Dahlbäck B, Carlson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Nat Acad Sci 1993; 90: 1004-1008
13. Dekker GA, de Vries J, Doelitsch PM, Huijgen PC, von Blomberg BM, Jacobs C. Underlying disorders associated with severe early onset preeclampsia. Am J Obstet Gynecol 1995; 173:1042-1048
14. Faden D, Tinlani A, Tanzi P, Spatola L, Lojascono A, Tarantini M, Balestieri G. Anti ß2 Glycoprotein l antibodies in a general obstetric population: Preliminary results on the prevalence and correlation with pregnancy outcome. Europ J Obstet Gynecol Reprod Biol 1997; 73: 37-42
15. Harris EN. Syndrome of the black swan. BrJ Rheumatol 1987; 26: 324-326
16. Hunt BJ, Doughty HA, Majundar G, Copplestone A, Kerslake S, Bouchanan N, Hughes G, Kamashta M. Thromboprophylaxis with low molecular weight heparin in high risk pregnancies. Thromb Haemostas 1997; 77: 39-43
17. Katamo K, Aoki A. Saso H, Ogasawara M, Matsuura E, Yagami Y. Beta 2 glycoprotein 1 dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcome in healthy pregnant women. Hum Reprod 1996; 11:509-512
18. Kraus M, Zander N, Fickenscher K. Coagulation assay with improved specifity to factor V mutants insensitive to activated protein C.Thromb Res 1995; SO: 255-264
19. Krnic-Barrie S, Riester O. Conner C. Looney StW, Pierangli SS, Harris EV. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med 1997; 157: 2101 -2108
20. Kraus T, Augustin HG, Osmers R, Meden H. Unterhalt M. Kühn W. Activated protein C resistance and factor V Leiden mutation in patients with hemolysis elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998; 92:457-460
21. Kupfermine MJ, Eldor A, Steinman N, Many A, Bar-An A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9-13
22. Lindoff C, Ingemarsson L, Martinsson G, Segelmark M, Thysell H. Astedt B. Preeclampsia is associated with a reduced response to activated protein C. AmJ Obstet Gynecol 1997; 176: 457-460
23. Pattison NS, Chamley LW, Makay EJ, Higgins GC. Antiphospholipid antibodies in pregnancy, prevalence and clinical association. BrJ Obstet Gynecol 1993; 100: 909-913
24. Peek MJ, Nelson Piercy C, Mannig RA, de Swiet M. Letsky EA. Activated protein C resistance in normal pregnancy. Br J Obstet Gynecol 1997; 104: 1084-1086
25. Pétri M. Pathogenesis and treatment of the antiphospholipid antibody syndrom. Adv in Rheumatol 1997; 81:151 -177
26. Rand JH. Wu XX, Andrée HAM, Lockwood ChJ, Gutler S, Sher J, Harpel PC. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. N Engl J Med 1997; 337:154-160
27. Reece EA, Gabrielli S, Cullen MT, Zheng XZ, Halbin JC, Harris EN. Recurrent adverse pregnancy outcome and antiphospholipid antibodies. AmJ Obstet Gynecol 1990; 163:162-169
28. Rees DC, Cox M, ClaggJB. Distribution of Factor V Leiden. Lancet 1995:346:1133-1134
29. Rote NS. Antiphospholipid antibodies and disorders of pregnancy.J Clin Immunoassay 1990; 13:34-42
30. Schneider DM, Heilmann L, Tempelhoff von GF, Kuse S, Knirsch K, Vogel W. Antiphospholipid antibodies and hematological defects in women with a history of preeclampsia/HELLP and outcome of IVIG treated pregnancies. Ann Hematol 1999; 78: 55
31. Sibai BM, Mercew B, Sarinoglu C. Severe preeclampsia in the second trimester recurrence risk and long term prognosis. Am J Obstet Gynecol 1991; 165:1408-1412
32. Sibai BM, Sarinoglu C, Mercew B. Eclampsia VII: Pregnancy outcome after eclampsia and longterm prognosis. Am J Obstet Gynecol 1992; 166:1757-1763
33. Spinnato JA, Clark AL, Pierangelli S, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. AmJ Obstet Gynecol 1995; 172: 690-694
34. Sullivan CA, Magann EF, Perry KG. Roberts WE, Blake PG, Martin JN. The recurrence risk of the syndrome of hemolysis elevated liver enzymes and low platelets (HELLP) in subsequent gestations. AmJ Obstet Gynecol 1994; 171: 940-943
35. Walker MC, Garner PR, Kelly EJ, Rock GA. Reis MD. Changes in activated protein C resistance during normal pregnancy. AmJ Obstet Gynecol 1997; 177:162-169